Abivax SA (ABVX) is trading at $118.95 up 3.62% over the past 24 hours. Its Galaxy Score is 72.0, LunarCrush's combined measure of market and social performance. Over the last 24 hours it has seen 143.1K engagements and 208 posts with 70% positive social sentiment.
AI summary: Abivax S.A. (ABVX) is a French clinical-stage biotech developing obefazimod for ulcerative colitis and IBD, trading on NASDAQ. The 0.66% daily slide and -12.3% 30-day drop came as Marshall Wace disclosed a short position and Sofinnova added sell pressure via Form 144 insider sales, stoking supply overhang despite social dominance surging 174% and retail buying on rumor pushing against bearish technicals.